Bradford J. Shafer Sells 14,670 Shares of Theravance Biopharma, Inc. (TBPH) Stock
Theravance Biopharma, Inc. (NASDAQ:TBPH) EVP Bradford J. Shafer sold 14,670 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the sale, the executive vice president now owns 134,327 shares in the company, valued at $4,133,241.79. The transaction was disclosed in a filing with the SEC, which is available through this link.
Theravance Biopharma, Inc. (NASDAQ TBPH) traded up 1.45% during trading on Friday, hitting $31.43. 108,085 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $30.21 and its 200 day moving average price is $35.22. Theravance Biopharma, Inc. has a 12-month low of $23.15 and a 12-month high of $43.44. The firm’s market cap is $1.69 billion.
ILLEGAL ACTIVITY NOTICE: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/08/bradford-j-shafer-sells-14670-shares-of-theravance-biopharma-inc-tbph-stock.html.
Institutional investors have recently added to or reduced their stakes in the stock. American International Group Inc. grew its stake in Theravance Biopharma by 16.4% in the 1st quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock valued at $894,000 after acquiring an additional 3,417 shares during the period. Harvest Management LLC acquired a new stake in Theravance Biopharma in the 1st quarter valued at $228,000. Parametric Portfolio Associates LLC grew its stake in Theravance Biopharma by 3.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock valued at $519,000 after acquiring an additional 456 shares during the period. Geode Capital Management LLC grew its stake in Theravance Biopharma by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock valued at $12,160,000 after acquiring an additional 18,177 shares during the period. Finally, American Century Companies Inc. acquired a new stake in Theravance Biopharma in the 1st quarter valued at $1,132,000. 84.54% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently weighed in on TBPH. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, August 16th. BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Evercore ISI assumed coverage on shares of Theravance Biopharma in a report on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 price target on the stock. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, Needham & Company LLC raised their price target on shares of Theravance Biopharma from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, May 11th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Theravance Biopharma currently has an average rating of “Hold” and a consensus price target of $41.63.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.